Raymond James & Associates’s Adient ADNT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q3
– Sell
-8,580
Closed -$208K – 3605
2019
Q2
$208K Buy
+8,580
New +$177K ﹤0.01% 3232
2018
Q4
– Sell
-181,468
Closed -$7.13M – 3537
2018
Q3
$7.13M Buy
181,468
+33,933
+23% +$1.53M 0.01% 1013
2018
Q2
$7.26M Buy
147,535
+13,736
+10% +$779K 0.01% 977
2018
Q1
$8M Sell
133,799
-14,558
-10% -$971K 0.01% 898
2017
Q4
$11.7M Buy
148,357
+22,686
+18% +$1.83M 0.02% 686
2017
Q3
$10.6M Buy
125,671
+26,214
+26% +$1.86M 0.02% 703
2017
Q2
$6.5M Buy
99,457
+66,966
+206% +$4.55M 0.01% 923
2017
Q1
$2.36M Buy
32,491
+22,471
+224% +$1.48M 0.01% 1434
2016
Q4
$587K Buy
+10,020
New +$529K ﹤0.01% 2238

Other funds holding ADNT

Raymond James & Associates's ADNT Position: Q3 2019 in Review

Raymond James & Associates sold out of Adient (ADNT) in Q3 2019, closing a stake of 8,580 shares — an estimated $208K sold.

Raymond James & Associates first reported a position in ADNT in Q4 2016 and held it in 9 quarters. The position peaked at $11.7M in Q4 2017. 307 funds tracked by Wall St. Rank hold ADNT as of Q3 2019.

  • Raymond James & Associates reported no remaining Adient position as of Q3 2019 after selling out during the quarter.
  • Raymond James & Associates sold 8,580 Adient shares in Q3 2019, an estimated $208K.
  • Raymond James & Associates first reported a position in Adient in Q4 2016 and held it in 9 quarters.
  • Raymond James & Associates's Adient position peaked at $11.7M in Q4 2017.
  • 307 funds tracked by Wall St. Rank held Adient as of Q3 2019.

Based on Raymond James & Associates's 13F filing for Q3 2019, filed 7 Nov 2019.